Scientific Program

Congress opening and greetings
Session A
Chairs: Huda Mussaffi ,MD and Malena Cohen-Cymberknoh, MD

9:00- 9:10

Welcome and introduction
Malena Cohen-Cymberknoh, MD; CF Center, Hadassah Medical Center, Jerusalem

9:10- 9:30

From Bedside to Bench - My CCHMC translational research experience

Galit Livnat, MD; Pediatric Pulmonology Unit and CF Center, Carmel Medical Center, Haifa

9:30- 9:45

Immunoglobulins as an indicator of disease severity

Sywar Shech Yosef  & Dario Prais, MD; Graub CF Center, Schneider Children's Medical Center, Petah Tikva

9:45- 10:00

Normal FEV1 in CF patients, how normal are the lungs?

Malena Cohen-Cymberknoh, MD; CF Center, Hadassah Medical Center, Jerusalem

10:00-10:15

FEV₁/FEV₃, helpful marker for ESLD IN CF

Moshe Ashkenazi, MD; The National Center for CF, Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Tel Hashomer

Session B
Chairs: Ori Efrati, MD and Inbal Golan-Tripto, MD
(Session conducted in English)

10:45-11:05

CFTR modulator outcomes in patients with severe disease

Michal Shteinberg, MD, PhD; CF Center, Carmel Medical Center, Haifa

11:05-11:25

Expected and unexpected gastrointestinal effects of CFTR modulation

Michael Wilschanski, MD; CF Center, Hadassah Medical Center, Jerusalem

11:25-11:45

The Israeli experience with Symdeko

Dario Prais, MD; Graub CF Center, Schneider Children's Medical Center, Petah Tikva

11:45-12:05

Until it’s done: Strategies to bring CFTR therapies to all CF patients

John Clancy, MD; Cystic Fibrosis Foundation, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati

Session C
Chairs: Hanna Blau, MBBS and Moshe Ashkenazi, MD
(Session conducted in English)

14:00- 14:20

Comprehensive evaluation of the Efficacy and Safety regarding endocrinology and bone metabolism of Lumacaftor /Ivacaftor (Orkambi) in Subjects with CF homozygous for the F508del-muation

Karin Yaacoby-Bianu, MD; CF Center, Carmel Medical Center, Haifa

14:20-14:40

Ivacaftor for patients with 3849 + 10KB C→T or D1152H Mutations:

The VX16-770-127 study results

Eitan Kerem, MD; CF Center, Hadassah Medical Center, Jerusalem

14:40-15:10

​"30 Years Progress to treatment for all patients"

Mark Higgins, MBBS; Vertex Pharmaceuticals Inc., Boston

15:10-15:30

A phase 1 PK and safety study of multiple doses of ELX-02

in healthy volunteers

Andi Leubitz,  Executive Director, Clinical Operations & Israel Site Head, Eloxx Pharmaceuticals Inc.

15:30-16:00

Theratyping approaches to bring modulators to patients with rare CFTR mutations

John Clancy, MD; Cystic Fibrosis Foundation, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati

Session D
Chairs: Lea Bentur, MD and David Shoseyov, MD
(Session conducted in English)

16:40-17:00 

The Israeli CF Registry Annual Data

Meir Mei Zahav, MD; Graub CF Center, Schneider Children's Medical Center,

Petah Tikva

17:00-17:20

Distribution of CFTR variants in the Middle East: review of literature and results of the ongoing genotyping project

Milan Maczek, MD, PhD;  Department of Biology and Medical Genetics, Charles University and Motol University Hospital, Prague, Czech Republic

17:20-17:35

Bone disease and pancreatic status

Maya Trau, MD &Dario Prais, MD; Graub CF Center, Schneider Children's Medical Center, Petah Tikva

17:35-17:50

The tale of one man

David Shoseyov, MD; CF Center, Hadassah Medical Center, Jerusalem

17:50-18:10

30 years after cloning the CF gene: what did we achieve and where are we going from here

Batsheva Kerem, PhD; Life Sciences Institute, Hebrew University, Jerusalem

Session E
Chairs: Michal Shteinberg, MD and Oded Breuer, MD
(Session conducted in English)

9:00- 9:15

ABPA and Nocardia – who is to blame?

Michal Gur, MD; CF Center Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa

09:15- 09:30

Aspergillus in young children with CF- guilty until proven innocent

Oded Breuer, MD; CF Center, Hadassah Medical Center, Jerusalem

09:30- 09:45

Nasal Potential Difference Testing in the work up of chronic lung disease in adults

Michael Cohen, MD; CF Center, Hadassah Medical Center, Jerusalem

09:45 -10:00

Case presentation

Einat Shmueli, MD; Graub CF Center, Schneider Children's Medical Center, Petah Tikva

10:00- 10:30

BEAT CF: An adaptive platform trial to study exacerbations of CF

Andre Schultz MBChB, PhD, FRACP, Child Health, School of Medicine, University of Western Australia, Perth, & Department of Respiratory Medicine, Perth Children's Hospital, Perth, Western Australia

Session F
Chairs: Galit Livnat, MD and Dario Prais, MD
(Session conducted in English)

11:00-11:30

An Australian perspective on physiotherapy clinical practice for children with CF

Pam Laird, PhD; Child Health, School of Medicine, University of Western Australia, Perth, & Department of Respiratory Medicine, Perth Children's Hospital, Perth, Western Australia

11:30 -11:50

Palliative care and advance care planning

Yulia Gendler, RN; Graub CF Center, Schneider Children's Medical Center, Petah Tikva

11:50- 12:10

Embarrassment and coughing: how much does it really bother me

Eddie Landau, PhD & Hagit Levin, MD; Graub CF Center, Schneider Children's Medical Center, Petah Tikva

12:10-12:20

Closing remarks

Malena Cohen-Cymberknoh, MD; CF Center, Hadassah Medical Center, Jerusalem

14:00

Professional group meetings:

CF Center Physicians

CF Nurses and Research Coordinators

CF Dieticians

CF Physiotherapists

CF Psychologists and social workers